Disseminated vascular papules in an immunodeficient patient being treated with granulocyte colony-stimulating factor

Journal of the American Academy of Dermatology

Volumn 49, Issue 1, 2003, Pages 105-108

  Lenczowski, Joi M ^a   Cassarino, David S ^a   Jain, Ashish ^b   Turner, Maria L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; FLUOXETINE; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; IMMUNOGLOBULIN;

ADULT; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CASE REPORT; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL FEATURE; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG RESPONSE; ENTEROVIRUS INFECTION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERIMMUNOGLOBULINEMIA M; IMMUNE DEFICIENCY; INFECTION; MALE; MENINGOENCEPHALITIS; NEUTROPENIA; OPTIC NERVE DISEASE; PAPULE; PRIORITY JOURNAL; PYOGENIC GRANULOMA; SKIN BIOPSY; SYMPTOM; VISUAL IMPAIRMENT; X CHROMOSOME LINKED DISORDER;

EID: 0038386271     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1067/mjd.2003.306     Document Type: Article

References (16)

1. North PE, Waner M, Mizeracke A, Mihm MC Jr. GLUT1: a newly discovered immunohistochemical marker for juvenile hemangiomas. Hum Pathol 2000;31:11-22.
2. North PE, Waner M, Mizeracki A, Mrak RE, Nicholas R, Kincannon J, et al. A unique microvascular phenotype shared by juvenile hemangiomas and human placenta. Arch Dermatol 2001;137: 559-70.
3. Juhlin L, Hjertquist SO, Ponten J, Wallin J. Disseminated granuloma pyogenicum. Acta Derm Venereol 1970;50:134-6.
4. Pembroke AC, Grice K, Levantine AV, Warin AP. Eruptive angiomata in malignant disease. Clin Exp Dermatol 1978;3:147-56.
5. de Kaminsky AR, Otero AC, Kaminsky CA, Shaw M, Formentini E, Abulafia J. Multiple disseminated pyogenic granuloma. Br J Dermatol 1978;98:461-5.
6. Nappi O, Wick MR. Disseminated lobular capillary hemangioma (pyogenic granuloma). Am J Dermatopathol 1986;8:379-85.
7. Wilson BB, Greer KE, Cooper PH. Eruptive disseminated lobular capillary hemangioma (pyogenic granuloma). J Am Acad Dermatol 1989;21:391-4.
8. Strohal R, Gillitzer R, Zonzits E, Stingl G. Localized vs generalized pyogenic granuloma. Arch Dermatol 1991;127:856-61.
9. Shah M, Kingston TP, Cotterill JA. Eruptive pyogenic granulomas: a successfully treated patient and review of the literature. Br J Dermatol 1995;133:795-6.
10. Viallard AM, Lavenue A, Balme B, Pincemaille B, Raudrant D, Thomas L. Lichenoid cutaneous drug reaction at injection sites of granulocyte colony-stimulating factor (Filgrastim). Dermatology 1999;198:301-3.
11. Vial T, Descotes J. Clinical toxicity of cytokines used as haemopoietic growth factors. Drug Safety 1995;13:371-406.
12. Bussolino F, Wang JM, Defilippi P, Turrini F, Savanio F, Edgell CJ, et al. Granulocyte- and granulocyte-macrophage colony-stimulating factors induce human endothelial cells to migrate and proliferate. Nature 1989;337:471-3.
13. Bussolino F, Ziche M, Wang JM, Alessi D, Morbidelli L, Cremona O, et al. In vitro and in vivo activation of endothelial cells by colony-stimulating factors. J Clin Invest 1991;87:986-95.
14. Notarangelo LD, Duse M, Ugazio AG. Immunodeficiency with hyper-IgM (HIM). Immunodefic Rev 1992;3:101-22.
15. Jain A, Atkinson TP, Lipsky PE, Slater JE, Nelson DL, Strober W. Defects of T cell effector function and post thymic maturation in X-linked hyper-IgM syndrome. J Clin Invest 1999;103:1151-8.
16. Levy J, Espanol-Boren T, Thomas C, Fischer A, Tovo P, Bordigoni P, et al. Clinical spectrum of X-linked hyper-IgM syndrome. J Pediatr 1997;131:47-54.